

Christine L Hann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3098004/publications.pdf>

Version: 2024-02-01

30
papers

1,629
citations

516710

16
h-index

580821

25
g-index

31
all docs

31
docs citations

31
times ranked

3077
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I open-label, dose escalation study. International Journal of Cancer, 2022, 150, 993-1006.	5.1	28
2	Validation of a rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of vistusertib. Journal of Pharmaceutical and Biomedical Analysis, 2022, 208, 114436.	2.8	1
3	Report of the First International Symposium on NUT Carcinoma. Clinical Cancer Research, 2022, 28, 2493-2505.	7.0	23
4	Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors. Anticancer Research, 2021, 41, 91-99.	1.1	4
5	CDKS Blockade Enhances In Vivo Efficacy of EGFR Inhibition in Chordomas. Journal of Neurological Surgery, Part B: Skull Base, 2021, 82, .	0.8	0
6	Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy. Lung Cancer, 2021, 154, 36-43.	2.0	29
7	Abstract 1617: Sex-specific genomic determinants of response to immunotherapy. , 2021, , .		0
8	AZD8055 enhances <i>in vivo</i> efficacy of afatinib in chordomas. Journal of Pathology, 2021, 255, 72-83.	4.5	9
9	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. JTO Clinical and Research Reports, 2021, 2, 100220.	1.1	4
10	Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. Neuro-Oncology Advances, 2021, 3, vdaa154.	0.7	13
11	Immunotherapy for small cell lung cancer: established applications and novel approaches. Clinical Advances in Hematology and Oncology, 2021, 19, 654-663.	0.3	0
12	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer, 2020, 1, 99-111.	13.2	141
13	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum, 2020, 4, pkz093.	2.9	126
14	Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurgery, 2020, 135, e187-e193.	1.3	19
15	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	1.1	119
16	BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. Journal of Clinical Oncology, 2020, 38, 3618-3618.	1.6	6
17	Establishment and Characterization of Two Novel Olfactory Neuroblastoma Cell Lines. Journal of Neurological Surgery, Part B: Skull Base, 2020, 81, .	0.8	0
18	Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 543-552.	3.8	17

#	ARTICLE	IF	CITATIONS
19	RARE-29. AZD8055 ENHANCES IN VIVO EFFICACY OF AFATINIB IN CHORDOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi227-vi227.	1.2	1
20	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 494-502.	1.1	114
21	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.9	226
22	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4305-4315.	8.2	100
23	Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma. <i>Nature Communications</i> , 2018, 9, 5410.	12.8	30
24	Pneumonitis in Nonâ€“Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1930-1939.	1.1	282
25	Lung and Thymic Carcinoids. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 699-709.	3.2	7
26	Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model. <i>PLoS ONE</i> , 2016, 11, e0151832.	2.5	64
27	A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis. <i>Nature Communications</i> , 2016, 7, 10339.	12.8	57
28	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
29	Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 2846-2856.	0.9	52
30	Inferior Vena Cava Interruption. , 0, , 99-109.		1